Peter Nygren – New and individualised cancer treatment
The main objective of our research is to improve the efficacy of cancer treatment by providing information allowing for optimal drug selection for the individual patient. We also want to identify and develop potentially new and more active cancer drugs.
Since the start of modern chemotherapy for cancer in the 1940s a number of drugs have become available. However, the doctor’s choice of medical treatment generally does not take into account the considerable variation that is known to exist between individual patients in terms of efficacy, tolerance and
pharmacokinetics. This means that many patients receive a
suboptimal treatment that often only results in side effects.
In recent years new drugs have been developed but the experience so far is that only a small fraction of treated patients might experience good effect of these drugs. At the group level, the benefit is mostly modest.
Our research has two main objectives. One is to is to provide predictive information that allows for optimal drug selection for an individual patient, and, as important, to exclude drugs that will not be active but only produce toxicity.
The second objective, and immediately related to the first, since it is based on the same technical platform as in objective one, is to identify new lead compounds with potentially improved efficacy against tumour types. Candidate drugs are identified and mechanistically characterized in cancer models in the laboratory, followed by testing in animal models with the aim to finally move them to clinical trials in cancer patients.
Since this second objective is based on the principle of drug repositioning, i.e. the application of drugs already in use for other indications for treatment of cancer, it lies within reach for academic research groups with limited funding to take findings all the way from the laboratory to early clinical testing.
Publications
Part of Cancer Research Communications, p. 28-37, 2024
- DOI for A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial
- Download full text (pdf) of A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial
Part of BMC Pharmacology & Toxicology, 2024
- DOI for Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
- Download full text (pdf) of Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
Part of Anti-Cancer Drugs, p. 92-102, 2023
- DOI for Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
- Download full text (pdf) of Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases
Part of British Journal of Surgery, p. 1080-1083, 2023
- DOI for Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases
- Download full text (pdf) of Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases
Part of BMC Cancer, 2023
- DOI for Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
- Download full text (pdf) of Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
Part of ESMO Open, 2023
Evaluation and validation of chemotherapy‐specific diarrhoea and histopathology in rats
Part of Basic & Clinical Pharmacology & Toxicology, p. 536-546, 2022
- DOI for Evaluation and validation of chemotherapy‐specific diarrhoea and histopathology in rats
- Download full text (pdf) of Evaluation and validation of chemotherapy‐specific diarrhoea and histopathology in rats
Part of International Journal of Oncology, 2022
- DOI for Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome
- Download full text (pdf) of Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome
Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
Part of Oncology Letters, 2022
- DOI for Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
- Download full text (pdf) of Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
Part of Scientific Reports, 2022
- DOI for Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
- Download full text (pdf) of Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
Part of Scientific Reports, 2021
- DOI for A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
- Download full text (pdf) of A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
Part of Scandinavian Journal of Medicine and Science in Sports, p. 1144-1159, 2021
- DOI for Does exercise intensity matter for fatigue during (neo)adjuvant cancer treatment?: The PhysCan randomized clinical trial
- Download full text (pdf) of Does exercise intensity matter for fatigue during (neo)adjuvant cancer treatment?: The PhysCan randomized clinical trial
Part of Läkartidningen, 2021
Part of Psycho-Oncology, p. 2012-2018, 2020
- DOI for Cocreated internet-based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: Results from the U-CARE AdultCan randomized controlled trial
- Download full text (pdf) of Cocreated internet-based stepped care for individuals with cancer and concurrent symptoms of anxiety and depression: Results from the U-CARE AdultCan randomized controlled trial
Part of Supportive Care in Cancer, p. 3331-3342, 2020
- DOI for Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.
- Download full text (pdf) of Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.
Part of Nutrition & Dietetics, p. 223-230, 2020
Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
Part of Nature Communications, 2020
- DOI for Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
- Download full text (pdf) of Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Part of Scientific Reports, 2020
- DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
- Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Part of Anticancer Research, p. 2771-2775, 2020
Part of Investigational new drugs, p. 684-692, 2019
Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer
Part of Acta Oncologica, p. 395-397, 2019
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Part of BMC Research Notes, 2019
- DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
- Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Part of Anticancer Research, p. 2509-2512, 2019
Part of Scandinavian Journal of Medicine and Science in Sports, p. 1274-1287, 2019
Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Part of Neuroendocrinology, p. 189-189, 2018
Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors
Part of Endocrine-Related Cancer, p. 471-480, 2018
Part of Acta Oncologica, p. 187-194, 2018
- DOI for U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.
- Download full text (pdf) of U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.
Part of Oncotarget, p. 103952-103967, 2017
- DOI for Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism
- Download full text (pdf) of Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism
Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
Part of Oncotarget, p. 30217-30234, 2017
- DOI for Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
- Download full text (pdf) of Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
Melflufen: a peptidase-potentiated alkylating agent in clinical trials
Part of Oncotarget, p. 66641-66655, 2017
- DOI for Melflufen: a peptidase-potentiated alkylating agent in clinical trials
- Download full text (pdf) of Melflufen: a peptidase-potentiated alkylating agent in clinical trials
Part of SLAS TECHNOLOGY, p. 306-314, 2017
Prognostic factors in patients with loco-regionally advanced gastric cancer
Part of World Journal of Surgical Oncology, 2017
- DOI for Prognostic factors in patients with loco-regionally advanced gastric cancer
- Download full text (pdf) of Prognostic factors in patients with loco-regionally advanced gastric cancer
Targeting tumor cells based on Phosphodiesterase 3A expression
Part of Experimental Cell Research, p. 308-315, 2017
Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017
Part of Cancer Nursing, 2017
- DOI for The development of a Nurse-led Internet-based Learning and Self-care program for cancer patients with symptoms of anxiety and depression: a part of U-CARE
- Download full text (pdf) of The development of a Nurse-led Internet-based Learning and Self-care program for cancer patients with symptoms of anxiety and depression: a part of U-CARE
Part of Leukemia Research, p. 41-46, 2017
- DOI for Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
- Download full text (pdf) of Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
Part of European Journal of Cancer Care, p. 516-523, 2016
Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy
Part of JALA, p. 178-187, 2016
Part of BMC Cancer, 2016
- DOI for High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer
- Download full text (pdf) of High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer
Iron chelators target both proliferating and quiescent cancer cells
Part of Scientific Reports, 2016
- DOI for Iron chelators target both proliferating and quiescent cancer cells
- Download full text (pdf) of Iron chelators target both proliferating and quiescent cancer cells
Part of CELL CHEMICAL BIOLOGY, p. 1428-1438, 2016
Part of Acta Oncologica, p. 1227-1235, 2016
Part of European Journal of Surgical Oncology, p. 1401-1406, 2016
Preclinical activity of melflufen (J1) in ovarian cancer
Part of Oncotarget, p. 59322-59335, 2016
Repositioning Of Quinacrine For Treatment Of Acute Myeloid Leukemia - Synergies And In Vivo Effects
Part of Haematologica, p. 367-368, 2016
Uptake, delivery, and anticancer activity of thymoquinone nanoparticles in breast cancer cells
Part of Journal of nanoparticle research, 2016
Always look at the bright side of drugs?
Part of Acta Oncologica, p. 145-147, 2015
Part of Annals of Surgery, 2015
Part of Blood Cancer Journal, 2015
- DOI for Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
- Download full text (pdf) of Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
Part of Annals of Surgical Oncology, 2015
Part of Investigational new drugs, p. 1232-1241, 2015
Part of European Journal of Cancer Care, p. 133-141, 2015
Part of Scientific Reports, 2015
- DOI for In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index
- Download full text (pdf) of In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index
Part of Chemometrics and Intelligent Laboratory Systems, p. 24-32, 2015
Part of Journal of Nuclear Medicine, p. 1144-1149, 2015
Part of Cancer Research, 2015
Part of Molecular Cancer Therapeutics, p. 1504-1516, 2015
Part of Molecular Cancer Therapeutics, p. 1964-1976, 2014
Part of Journal of Experimental & Clinical Cancer Research, 2014
- DOI for Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy
- Download full text (pdf) of Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy
Part of Acta Oncologica, p. 242-250, 2014
Part of Radiotherapy and Oncology, p. 240-247, 2014
Part of Nature Communications, p. 3295, 2014
- DOI for Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
- Download full text (pdf) of Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
Repositioning of Quinacrine for Treatment of Acute Myeloid Leukemia
Part of Blood, 2014
Part of Anticancer Research, p. 289-293, 2014
Part of BMC Cancer, p. 435, 2013
- DOI for Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer
- Download full text (pdf) of Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer
Part of Annals of Surgical Oncology, p. 4183-4189, 2013
Part of BMC Cancer, p. 414, 2013
- DOI for Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer: a clinical trial protocol
- Download full text (pdf) of Internet-based stepped care with interactive support and cognitive behavioral therapy for reduction of anxiety and depressive symptoms in cancer: a clinical trial protocol
Part of European Journal of Clinical Pharmacology, p. 533-540, 2013
Part of Supportive Care in Cancer, p. 3137-3142, 2013
Part of Acta Oncologica, p. 824-830, 2013
Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells
Part of Biochemical and Biophysical Research Communications - BBRC, p. 117-123, 2013
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Part of Journal of Cancer Research and Clinical Oncology, p. 2133-2140, 2013
- DOI for Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
- Download full text (pdf) of Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Part of BMC Cancer, p. 374, 2013
- DOI for Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
- Download full text (pdf) of Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
The Nanoparticulate Quillaja Saponin BBE Is Selectively Active Towards Renal Cell Carcinoma
Part of Anticancer Research, p. 143-151, 2013
Part of Acta Oncologica, p. 112-121, 2012
Part of European Journal of Surgical Oncology, p. 509-515, 2012
- DOI for Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis: Prognosis and Treatment of Recurrences in a Cohort Study
- Download full text (pdf) of Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis: Prognosis and Treatment of Recurrences in a Cohort Study
Evaluation of predictive markers for patients with advanced colorectal cancer
Part of Acta Oncologica, p. 849-859, 2012
Part of Anticancer Research, p. 1443-1448, 2012
Part of Cancer Chemotherapy and Pharmacology, p. 697-707, 2012
Part of Annals of Oncology, p. 647-652, 2012
- DOI for Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study
- Download full text (pdf) of Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study
Part of Experimental Cell Research, p. 1577-1585, 2012
Part of European Journal of Surgical Oncology, p. 962-968, 2012
Part of Annals of Surgery, p. 1078-1083, 2012
Pseudomyxoma Peritone: symptoms, treatment, prognosis and sensitivity to cytostatic drugs in vitro
Part of Acta Obstetricia et Gynecologica Scandinavica, p. 71-71, 2012
2012
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2012
Response to comments on 'Cytoreductive surgery and intraperitoneal chemotherapy'
Part of European Journal of Surgical Oncology, p. 1012-1012, 2012
Part of International Journal of Oncology, p. 176-184, 2012
- DOI for The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines
- Download full text (pdf) of The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines
Part of Annals of Oncology, p. 948-954, 2012
Aminopeptidase N (CD13) as a target for cancer chemotherapy
Part of Cancer Science, p. 501-508, 2011
Part of Clinical Colorectal Cancer, p. 108-112, 2011
Part of Oncology Reports, p. 3-11, 2011
Novel activity of acriflavine against colorectal cancer tumor cells
Part of Cancer Science, p. 2206-2213, 2011
Part of Biochemical Pharmacology, p. 139-147, 2011
Part of Medical Oncology, p. 65-72, 2010
Part of Oncology Reports, p. 1645-1652, 2010
Part of Anti-Cancer Drugs, p. 33-42, 2010
Part of International Journal of Nanomedicine, p. 51-62, 2010
Part of Cancer Chemotherapy and Pharmacology, p. 1165-1172, 2010
Part of Investigational new drugs, p. 402-411, 2009